Optimal time for pharmacological treatment of abdominal aortic aneurysm

Y Iida, S Sawa, H Shimizu - Current drug targets, 2018 - ingentaconnect.com
Background: Abdominal aortic aneurysm (AAA), if left untreated, poses the main risks of
progressive expansion, rupture, and hemorrhage, leading to death. Large AAA with a risk of …

Pharmaceutical management of small abdominal aortic aneurysms: A systematic review of the clinical evidence

VBC Kokje, JF Hamming… - Journal of Vascular …, 2015 - jvascsurg.org
Background Management of abdominal aortic aneurysms (AAAs) relies on surgical repair of
larger AAAs. Consequently medical interventions inhibiting AAA progression could greatly …

Standardization of outcome measures in clinical trials of pharmacological treatment for abdominal aortic aneurysm

XL Wang, MM Thompson, WP Dole… - Expert review of …, 2012 - Taylor & Francis
An abdominal aortic aneurysm (AAA) is a common aortic wall disease with an increased
prevalence in the elderly population (4–8% for those aged> 65 years). Many AAAs are slow …

Towards Precritical Medical Therapy of the Abdominal Aortic Aneurysm

L Musumeci, W Eilenberg, J Pincemail, K Yoshimura… - Biomedicines, 2022 - mdpi.com
Pharmacotherapy for abdominal aortic aneurysm (AAA) can be useful for prevention,
especially in people at higher risk, for slowing down AAA progression, as well as for post …

[HTML][HTML] Editor's choice–pharmaceutical management of small abdominal aortic aneurysms: a systematic review of the clinical evidence

VBC Kokje, JF Hamming, JHN Lindeman - European Journal of Vascular …, 2015 - Elsevier
Background Management of abdominal aortic aneurysms (AAAs) relies on surgical repair of
larger AAAs. Consequently medical interventions inhibiting AAA progression could greatly …

Current theories and clinical trial evidence for limiting human abdominal aortic aneurysm growth

J Yu, S Liu, J Huang, W Wang - Current drug targets, 2018 - ingentaconnect.com
Background: Abdominal aortic aneurysm (AAA) refers to localized dilation of abdominal
aorta. AAA is largely asymptomatic, but aneurysmal rupture results in a high mortality rate …

Pharmacological therapy for patients with abdominal aortic aneurysm

AN Assar - Expert review of cardiovascular therapy, 2009 - Taylor & Francis
Abdominal aortic aneurysm (AAA) is a common and life-threatening disease characterized
by progressive dilatation and rupture, and has a mortality rate of up to 90%. Surgical repair …

Pharmacotherapy in clinical trials for abdominal aortic aneurysms: A systematic review and meta-analysis

Z Su, J Guo, Y Gu - Clinical and Applied Thrombosis …, 2022 - journals.sagepub.com
Objective There is no medical treatment proven to limit abdominal aortic aneurysm (AAA)
progression. This systematic review aimed to summarise available trial evidence on the …

Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture

RA Fraga-Silva, B Trachet… - Current pharmaceutical …, 2015 - ingentaconnect.com
Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused
by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in …

Current status and perspectives on pharmacologic therapy for abdominal aortic aneurysm

K Yoshimura, N Morikage… - Current drug …, 2018 - ingentaconnect.com
Background: Abdominal aortic aneurysm (AAA), a common disease involving the segmental
expansion and rupture of the aorta, has a high mortality rate. Therapeutic options for AAA …